Loading
Loading
Research Overview
Next-generation amylin analogue with enhanced AMY1-3 receptor affinity and pegylated pharmacokinetics enabling once-weekly dosing; activates brainstem and hypothalamic amylin receptors to produce appetite suppression and satiety complementary to GLP-1R agonism.
Petrelintide is a synthetic amylin analogue engineered for once-weekly subcutaneous administration, achieving this dosing frequency through structural modifications that enhance amylin receptor binding affinity and incorporate pharmacokinetic improvements (including pegylation) to extend half-life to approximately 8 days.
The amylin pathway provides appetite suppression and satiety signalling through brainstem and hypothalamic amylin receptors (AMY1-3) — a mechanism complementary to GLP-1 receptor agonism. Research has shown that combining GLP-1 and amylin pathway activation produces additive weight reduction beyond either alone, which has driven development of amylin analogues intended for combination with GLP-1 agonists.
Phase 2 data for petrelintide has demonstrated dose-dependent weight reduction with a generally milder gastrointestinal side effect profile than GLP-1 monotherapy, potentially enabling higher combined doses when used alongside semaglutide. The CagriSema (cagrilintide + semaglutide) combination programme has informed petrelintide's development direction.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, petrelintide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Petrelintide research is most relevant to protocols examining:
Next-generation weekly amylin analogue research
AMY1-3 receptor pharmacology studies with improved half-life
Combination obesity treatment research pairing amylin with GLP-1 agonists
Researchers comparing Petrelintide vs Cagrilintide pharmacodynamics
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~8 days (pegylated)). Review data, confirm baseline recovery before any repeat protocol.
Next-generation amylin analogue with enhanced AMY1-3 receptor affinity and pegylated pharmacokinetics enabling once-weekly dosing; activates brainstem and hypothalamic amylin receptors to produce appetite suppression and satiety complementary to GLP-1R agonism.
| Parameter | Value |
|---|---|
| Dose range | 0.3 mg initial |
| Alt. dose 2 | titrated up to 9 mg/week (trial range) |
| Schedule | Once weekly |
| Route | Subcutaneous |
| Half-life | ~8 days (pegylated) |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.